 Laura Ramsey
Concepts (377)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacogenetics | 33 | 2024 | 176 | 7.960 |
Why?
| | Methotrexate | 13 | 2024 | 30 | 5.490 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 20 | 2024 | 52 | 4.550 |
Why?
| | Humans | 93 | 2024 | 6896 | 3.810 |
Why?
| | Cytochrome P-450 CYP2D6 | 16 | 2024 | 184 | 3.700 |
Why?
| | Sertraline | 8 | 2024 | 11 | 3.600 |
Why?
| | Antipsychotic Agents | 4 | 2024 | 14 | 3.090 |
Why?
| | Anxiety Disorders | 9 | 2021 | 19 | 3.070 |
Why?
| | Child | 47 | 2024 | 3364 | 3.040 |
Why?
| | Adolescent | 38 | 2024 | 2197 | 2.970 |
Why?
| | Depressive Disorder | 5 | 2022 | 7 | 2.530 |
Why?
| | Antimetabolites, Antineoplastic | 8 | 2024 | 26 | 2.520 |
Why?
| | Citalopram | 9 | 2024 | 14 | 2.470 |
Why?
| | Genotype | 22 | 2024 | 410 | 2.260 |
Why?
| | Male | 37 | 2024 | 3337 | 2.090 |
Why?
| | Cytochrome P-450 CYP2C19 | 10 | 2024 | 60 | 1.990 |
Why?
| | Precision Medicine | 10 | 2024 | 45 | 1.980 |
Why?
| | Polymorphism, Single Nucleotide | 12 | 2023 | 348 | 1.940 |
Why?
| | Antineoplastic Agents | 5 | 2021 | 55 | 1.830 |
Why?
| | Retrospective Studies | 16 | 2024 | 1296 | 1.790 |
Why?
| | Female | 34 | 2024 | 3525 | 1.750 |
Why?
| | Antidepressive Agents | 10 | 2024 | 20 | 1.730 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2022 | 23 | 1.720 |
Why?
| | Phenotype | 9 | 2024 | 257 | 1.670 |
Why?
| | Dexamethasone | 7 | 2019 | 29 | 1.650 |
Why?
| | Organic Anion Transporters | 5 | 2014 | 8 | 1.510 |
Why?
| | Alleles | 7 | 2022 | 214 | 1.340 |
Why?
| | gamma-Glutamyl Hydrolase | 2 | 2020 | 2 | 1.340 |
Why?
| | Child, Preschool | 18 | 2024 | 1569 | 1.330 |
Why?
| | Asparaginase | 9 | 2024 | 13 | 1.270 |
Why?
| | Depressive Disorder, Major | 4 | 2024 | 14 | 1.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2019 | 39 | 1.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 66 | 1.130 |
Why?
| | Pediatrics | 3 | 2024 | 186 | 1.100 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 85 | 1.080 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 42 | 1.050 |
Why?
| | Acute Kidney Injury | 3 | 2024 | 30 | 1.030 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 5 | 2024 | 7 | 1.000 |
Why?
| | Nausea | 2 | 2021 | 16 | 0.980 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2024 | 94 | 0.950 |
Why?
| | Hyperprolactinemia | 1 | 2024 | 1 | 0.940 |
Why?
| | Bipolar Disorder | 2 | 2024 | 4 | 0.940 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2021 | 18 | 0.910 |
Why?
| | Mood Disorders | 2 | 2020 | 7 | 0.910 |
Why?
| | Fluoxetine | 2 | 2021 | 5 | 0.900 |
Why?
| | Serotonin and Noradrenaline Reuptake Inhibitors | 2 | 2023 | 4 | 0.900 |
Why?
| | Medicaid | 1 | 2024 | 38 | 0.900 |
Why?
| | Receptor, Serotonin, 5-HT2A | 3 | 2020 | 3 | 0.890 |
Why?
| | Tacrolimus | 1 | 2023 | 10 | 0.890 |
Why?
| | Mice, Knockout | 3 | 2021 | 59 | 0.880 |
Why?
| | Pharmacokinetics | 1 | 2023 | 14 | 0.880 |
Why?
| | Adult | 11 | 2024 | 1181 | 0.850 |
Why?
| | Chronic Pain | 1 | 2023 | 32 | 0.840 |
Why?
| | Tetrahydrofolates | 1 | 2022 | 3 | 0.840 |
Why?
| | Kidney Transplantation | 1 | 2023 | 115 | 0.830 |
Why?
| | Mice | 16 | 2021 | 348 | 0.810 |
Why?
| | Pharmaceutical Preparations | 3 | 2023 | 37 | 0.810 |
Why?
| | Antiemetics | 1 | 2021 | 4 | 0.800 |
Why?
| | Arthritis | 1 | 2021 | 1 | 0.780 |
Why?
| | Antirheumatic Agents | 1 | 2021 | 12 | 0.780 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 18 | 0.760 |
Why?
| | Prescription Drugs | 1 | 2020 | 4 | 0.750 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 41 | 0.750 |
Why?
| | Depression | 3 | 2024 | 69 | 0.750 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 50 | 0.750 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 16 | 0.740 |
Why?
| | Psychopharmacology | 1 | 2020 | 1 | 0.740 |
Why?
| | Aripiprazole | 1 | 2020 | 1 | 0.740 |
Why?
| | Animals | 16 | 2021 | 729 | 0.740 |
Why?
| | Infant | 12 | 2024 | 1446 | 0.740 |
Why?
| | Child Health Services | 1 | 2020 | 24 | 0.740 |
Why?
| | Decision Support Techniques | 1 | 2020 | 6 | 0.730 |
Why?
| | Piperazines | 2 | 2019 | 3 | 0.730 |
Why?
| | Models, Theoretical | 1 | 2020 | 13 | 0.730 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 187 | 0.730 |
Why?
| | Osteonecrosis | 6 | 2019 | 6 | 0.710 |
Why?
| | Psychotic Disorders | 1 | 2019 | 1 | 0.700 |
Why?
| | Anxiety | 2 | 2021 | 51 | 0.700 |
Why?
| | Young Adult | 6 | 2023 | 647 | 0.690 |
Why?
| | Neoplasms | 2 | 2022 | 128 | 0.680 |
Why?
| | Receptors, Kainic Acid | 1 | 2019 | 1 | 0.680 |
Why?
| | Genome-Wide Association Study | 6 | 2017 | 190 | 0.660 |
Why?
| | Weight Gain | 1 | 2018 | 23 | 0.630 |
Why?
| | Program Development | 1 | 2018 | 12 | 0.630 |
Why?
| | Simvastatin | 3 | 2022 | 10 | 0.630 |
Why?
| | Biomedical Research | 2 | 2024 | 27 | 0.620 |
Why?
| | Glucocorticoids | 2 | 2017 | 32 | 0.610 |
Why?
| | Treatment Outcome | 9 | 2020 | 622 | 0.600 |
Why?
| | Muscular Diseases | 2 | 2014 | 2 | 0.590 |
Why?
| | Methyltransferases | 2 | 2014 | 9 | 0.580 |
Why?
| | Computational Biology | 1 | 2017 | 43 | 0.580 |
Why?
| | Patient Care Management | 1 | 2017 | 3 | 0.580 |
Why?
| | B-Lymphocytes | 5 | 2017 | 24 | 0.580 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 108 | 0.570 |
Why?
| | United States | 6 | 2024 | 669 | 0.500 |
Why?
| | Electronic Health Records | 3 | 2020 | 64 | 0.500 |
Why?
| | Genetic Variation | 3 | 2021 | 174 | 0.450 |
Why?
| | Receptors, Antigen, B-Cell | 2 | 2010 | 4 | 0.450 |
Why?
| | Neoplasm Proteins | 2 | 2022 | 31 | 0.450 |
Why?
| | Polymorphism, Genetic | 4 | 2019 | 90 | 0.420 |
Why?
| | Follow-Up Studies | 5 | 2024 | 304 | 0.420 |
Why?
| | Prospective Studies | 5 | 2023 | 525 | 0.410 |
Why?
| | Genome, Human | 1 | 2013 | 86 | 0.410 |
Why?
| | Exons | 1 | 2011 | 34 | 0.400 |
Why?
| | Genetic Testing | 3 | 2021 | 87 | 0.380 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 336 | 0.380 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2010 | 1 | 0.370 |
Why?
| | raf Kinases | 1 | 2010 | 1 | 0.370 |
Why?
| | Calcium Signaling | 1 | 2010 | 4 | 0.370 |
Why?
| | Drug Hypersensitivity | 3 | 2015 | 19 | 0.370 |
Why?
| | Leukemia | 2 | 2024 | 15 | 0.360 |
Why?
| | Genotyping Techniques | 3 | 2021 | 22 | 0.340 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 45 | 0.340 |
Why?
| | Recombinant Proteins | 2 | 2020 | 48 | 0.330 |
Why?
| | Prognosis | 5 | 2024 | 211 | 0.320 |
Why?
| | Risk Factors | 9 | 2019 | 487 | 0.310 |
Why?
| | Drug Prescriptions | 4 | 2021 | 20 | 0.300 |
Why?
| | Haplotypes | 2 | 2022 | 91 | 0.300 |
Why?
| | Gene Frequency | 2 | 2021 | 90 | 0.300 |
Why?
| | Hypertriglyceridemia | 2 | 2019 | 5 | 0.300 |
Why?
| | Infusions, Intravenous | 2 | 2020 | 26 | 0.290 |
Why?
| | STAT5 Transcription Factor | 3 | 2017 | 6 | 0.270 |
Why?
| | Time Factors | 2 | 2018 | 250 | 0.270 |
Why?
| | DNA-Binding Proteins | 3 | 2018 | 39 | 0.260 |
Why?
| | Cytochrome P-450 Enzyme System | 3 | 2022 | 96 | 0.260 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 2 | 0.250 |
Why?
| | Lymphoma | 1 | 2024 | 9 | 0.250 |
Why?
| | Hypoalbuminemia | 1 | 2024 | 5 | 0.240 |
Why?
| | Drug Monitoring | 1 | 2024 | 13 | 0.240 |
Why?
| | Central Nervous System Neoplasms | 1 | 2024 | 6 | 0.240 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 41 | 0.240 |
Why?
| | Pharmacology, Clinical | 1 | 2024 | 4 | 0.240 |
Why?
| | Paliperidone Palmitate | 1 | 2024 | 2 | 0.230 |
Why?
| | Cyclohexanols | 1 | 2024 | 1 | 0.230 |
Why?
| | Risperidone | 1 | 2024 | 2 | 0.230 |
Why?
| | Primary Health Care | 1 | 2024 | 42 | 0.230 |
Why?
| | Bayes Theorem | 1 | 2024 | 30 | 0.230 |
Why?
| | Cytochrome P-450 CYP2C19 Inhibitors | 1 | 2023 | 1 | 0.230 |
Why?
| | Drug Labeling | 2 | 2020 | 4 | 0.230 |
Why?
| | Fluconazole | 1 | 2023 | 2 | 0.230 |
Why?
| | Oxycodone | 1 | 2023 | 4 | 0.220 |
Why?
| | Codeine | 1 | 2023 | 15 | 0.220 |
Why?
| | Databases, Factual | 1 | 2024 | 108 | 0.220 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2020 | 12 | 0.220 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 31 | 0.220 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2023 | 46 | 0.220 |
Why?
| | Medicine | 1 | 2022 | 10 | 0.210 |
Why?
| | Education, Distance | 1 | 2022 | 6 | 0.210 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2022 | 6 | 0.210 |
Why?
| | Inactivation, Metabolic | 2 | 2020 | 15 | 0.210 |
Why?
| | Drug Interactions | 3 | 2020 | 32 | 0.200 |
Why?
| | Ohio | 2 | 2019 | 9 | 0.200 |
Why?
| | Ondansetron | 1 | 2021 | 3 | 0.200 |
Why?
| | Mice, Inbred C57BL | 4 | 2015 | 92 | 0.200 |
Why?
| | Vomiting | 1 | 2021 | 23 | 0.200 |
Why?
| | Signal Transduction | 5 | 2020 | 132 | 0.200 |
Why?
| | Collagen | 1 | 2021 | 3 | 0.200 |
Why?
| | Receptors, Opioid, mu | 1 | 2021 | 4 | 0.200 |
Why?
| | Severity of Illness Index | 2 | 2019 | 149 | 0.190 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 14 | 0.190 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 22 | 0.190 |
Why?
| | Anti-Anxiety Agents | 1 | 2020 | 5 | 0.190 |
Why?
| | Psychotropic Drugs | 1 | 2020 | 3 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 3 | 2017 | 231 | 0.180 |
Why?
| | Hydrolysis | 1 | 2020 | 3 | 0.180 |
Why?
| | Transcription Factors | 2 | 2018 | 52 | 0.180 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 17 | 0.180 |
Why?
| | Biomarkers, Tumor | 2 | 2017 | 65 | 0.180 |
Why?
| | Drug Compounding | 1 | 2019 | 1 | 0.170 |
Why?
| | Mental Disorders | 1 | 2020 | 16 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2017 | 31 | 0.170 |
Why?
| | Thyroid Diseases | 1 | 2019 | 1 | 0.170 |
Why?
| | Thyrotropin | 1 | 2019 | 3 | 0.170 |
Why?
| | Membrane Proteins | 2 | 2017 | 54 | 0.170 |
Why?
| | Dasatinib | 1 | 2019 | 2 | 0.170 |
Why?
| | Tissue Distribution | 1 | 2019 | 11 | 0.170 |
Why?
| | Aged | 4 | 2024 | 378 | 0.160 |
Why?
| | Natural Language Processing | 1 | 2018 | 3 | 0.160 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 2 | 0.160 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2015 | 7 | 0.160 |
Why?
| | Disease Models, Animal | 2 | 2016 | 71 | 0.160 |
Why?
| | Neoplasm Transplantation | 2 | 2015 | 8 | 0.160 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 4 | 0.150 |
Why?
| | HLA-DRB1 Chains | 2 | 2015 | 5 | 0.150 |
Why?
| | Receptor, PAR-2 | 1 | 2017 | 1 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2017 | 8 | 0.150 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 16 | 0.150 |
Why?
| | Consensus | 1 | 2017 | 35 | 0.150 |
Why?
| | Dyslipidemias | 1 | 2017 | 15 | 0.150 |
Why?
| | Lipase | 1 | 2017 | 2 | 0.150 |
Why?
| | Pre-B Cell Receptors | 1 | 2017 | 1 | 0.150 |
Why?
| | Ikaros Transcription Factor | 1 | 2017 | 3 | 0.150 |
Why?
| | Alanine Transaminase | 1 | 2017 | 10 | 0.150 |
Why?
| | Systems Integration | 1 | 2017 | 6 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2015 | 26 | 0.140 |
Why?
| | Double-Blind Method | 3 | 2021 | 44 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 59 | 0.140 |
Why?
| | Mutation | 3 | 2018 | 212 | 0.140 |
Why?
| | Trans-Activators | 2 | 2017 | 14 | 0.130 |
Why?
| | Corticosterone | 1 | 2015 | 1 | 0.130 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2015 | 9 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2015 | 45 | 0.130 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 35 | 0.130 |
Why?
| | NFATC Transcription Factors | 1 | 2015 | 1 | 0.130 |
Why?
| | Caspase 1 | 1 | 2015 | 1 | 0.130 |
Why?
| | Receptors, Glucocorticoid | 1 | 2015 | 5 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2015 | 35 | 0.130 |
Why?
| | Premedication | 1 | 2015 | 2 | 0.130 |
Why?
| | Antibodies | 1 | 2014 | 15 | 0.120 |
Why?
| | Germ Cells | 1 | 2014 | 5 | 0.120 |
Why?
| | bcl-X Protein | 1 | 2013 | 2 | 0.120 |
Why?
| | Janus Kinase 2 | 1 | 2013 | 8 | 0.120 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 3 | 0.120 |
Why?
| | Serotonin | 2 | 2023 | 4 | 0.110 |
Why?
| | Homeodomain Proteins | 2 | 2012 | 20 | 0.110 |
Why?
| | Leucovorin | 1 | 2012 | 2 | 0.110 |
Why?
| | Linear Models | 1 | 2012 | 56 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2012 | 71 | 0.110 |
Why?
| | Recurrence | 1 | 2013 | 110 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2012 | 7 | 0.100 |
Why?
| | B-Lymphocyte Subsets | 1 | 2012 | 1 | 0.100 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2012 | 1 | 0.100 |
Why?
| | Interleukin-7 | 1 | 2012 | 2 | 0.100 |
Why?
| | Middle Aged | 3 | 2024 | 608 | 0.100 |
Why?
| | Cell Cycle | 1 | 2012 | 18 | 0.100 |
Why?
| | Organic Cation Transport Proteins | 1 | 2011 | 1 | 0.100 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2011 | 4 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2012 | 47 | 0.100 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 99 | 0.090 |
Why?
| | Cohort Studies | 1 | 2011 | 289 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2016 | 29 | 0.090 |
Why?
| | Adolescent Psychiatry | 2 | 2021 | 3 | 0.090 |
Why?
| | Risk Assessment | 3 | 2017 | 137 | 0.090 |
Why?
| | Recombination, Genetic | 1 | 2009 | 5 | 0.080 |
Why?
| | Immunoglobulins | 1 | 2009 | 6 | 0.080 |
Why?
| | Cell Cycle Proteins | 1 | 2009 | 18 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2018 | 35 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2009 | 15 | 0.080 |
Why?
| | Immunoglobulin Light Chains | 1 | 2008 | 2 | 0.080 |
Why?
| | Antigens | 1 | 2008 | 3 | 0.080 |
Why?
| | Genomics | 2 | 2022 | 101 | 0.070 |
Why?
| | Remission Induction | 2 | 2017 | 24 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 2 | 2017 | 18 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2017 | 32 | 0.060 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2024 | 4 | 0.060 |
Why?
| | Serum Albumin | 1 | 2024 | 9 | 0.060 |
Why?
| | ROC Curve | 1 | 2024 | 22 | 0.060 |
Why?
| | Mucositis | 1 | 2024 | 3 | 0.060 |
Why?
| | Neutropenia | 1 | 2024 | 12 | 0.060 |
Why?
| | Quality of Health Care | 1 | 2024 | 13 | 0.060 |
Why?
| | Patient Selection | 1 | 2024 | 40 | 0.060 |
Why?
| | Psychomotor Agitation | 1 | 2024 | 1 | 0.060 |
Why?
| | Desvenlafaxine Succinate | 1 | 2024 | 1 | 0.060 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2024 | 2 | 0.060 |
Why?
| | Biomarkers | 1 | 2024 | 136 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2015 | 44 | 0.060 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2023 | 11 | 0.060 |
Why?
| | Norepinephrine | 1 | 2023 | 12 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 55 | 0.050 |
Why?
| | Health Personnel | 1 | 2022 | 25 | 0.050 |
Why?
| | Seizures | 1 | 2022 | 25 | 0.050 |
Why?
| | Rosuvastatin Calcium | 1 | 2022 | 5 | 0.050 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2022 | 25 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2021 | 48 | 0.050 |
Why?
| | Research | 1 | 2021 | 13 | 0.050 |
Why?
| | Electronic Prescribing | 1 | 2021 | 1 | 0.050 |
Why?
| | Amygdala | 1 | 2021 | 3 | 0.050 |
Why?
| | Reimbursement Mechanisms | 1 | 2020 | 3 | 0.050 |
Why?
| | Area Under Curve | 1 | 2020 | 35 | 0.050 |
Why?
| | Patient Care | 1 | 2020 | 6 | 0.050 |
Why?
| | VDJ Recombinases | 2 | 2011 | 2 | 0.050 |
Why?
| | Software | 1 | 2020 | 30 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2020 | 33 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2012 | 59 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 122 | 0.040 |
Why?
| | Marketing of Health Services | 1 | 2019 | 3 | 0.040 |
Why?
| | Barrett Esophagus | 1 | 1999 | 2 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 1999 | 2 | 0.040 |
Why?
| | Ecological Parameter Monitoring | 1 | 2019 | 1 | 0.040 |
Why?
| | Sequence Analysis | 1 | 2019 | 3 | 0.040 |
Why?
| | Heterografts | 1 | 2019 | 3 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 11 | 0.040 |
Why?
| | Sex Factors | 1 | 2019 | 68 | 0.040 |
Why?
| | Prevalence | 1 | 2019 | 146 | 0.040 |
Why?
| | Decision Support Systems, Clinical | 1 | 2019 | 17 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2019 | 39 | 0.040 |
Why?
| | Mutagenesis, Insertional | 1 | 2018 | 1 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2018 | 5 | 0.040 |
Why?
| | Age Factors | 1 | 2019 | 210 | 0.040 |
Why?
| | Quality Improvement | 1 | 2019 | 60 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2009 | 84 | 0.040 |
Why?
| | Child Psychiatry | 1 | 2018 | 2 | 0.040 |
Why?
| | Catechol O-Methyltransferase | 1 | 2018 | 5 | 0.040 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 11 | 0.040 |
Why?
| | Protein Kinase C beta | 1 | 2017 | 1 | 0.040 |
Why?
| | Interferon Regulatory Factors | 1 | 2017 | 4 | 0.040 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2017 | 2 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 7 | 0.040 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2017 | 9 | 0.040 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2017 | 9 | 0.040 |
Why?
| | Survival Rate | 1 | 2017 | 83 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2017 | 33 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 41 | 0.040 |
Why?
| | Drug Synergism | 1 | 2016 | 7 | 0.030 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2015 | 1 | 0.030 |
Why?
| | Escherichia coli | 1 | 2016 | 30 | 0.030 |
Why?
| | Enzyme Replacement Therapy | 1 | 2015 | 4 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 3 | 0.030 |
Why?
| | Inflammasomes | 1 | 2015 | 2 | 0.030 |
Why?
| | Proteolysis | 1 | 2015 | 3 | 0.030 |
Why?
| | Prednisolone | 1 | 2015 | 5 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2015 | 25 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 25 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2015 | 32 | 0.030 |
Why?
| | Base Sequence | 1 | 2015 | 81 | 0.030 |
Why?
| | Fasting | 1 | 2014 | 4 | 0.030 |
Why?
| | Lipids | 1 | 2014 | 8 | 0.030 |
Why?
| | Pancreatitis | 1 | 2014 | 8 | 0.030 |
Why?
| | Thromboembolism | 1 | 2014 | 3 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 9 | 0.030 |
Why?
| | Epitopes | 1 | 2014 | 20 | 0.030 |
Why?
| | DNA Methylation | 1 | 2015 | 115 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 2013 | 1 | 0.030 |
Why?
| | Nitrophenols | 1 | 2013 | 2 | 0.030 |
Why?
| | Nitriles | 1 | 2013 | 3 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 6 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2013 | 7 | 0.030 |
Why?
| | Pyrazoles | 1 | 2013 | 3 | 0.030 |
Why?
| | Mice, SCID | 1 | 2013 | 13 | 0.030 |
Why?
| | Pyrimidines | 1 | 2013 | 7 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2013 | 7 | 0.030 |
Why?
| | Cell Survival | 1 | 2013 | 20 | 0.030 |
Why?
| | Sulfonamides | 1 | 2013 | 10 | 0.030 |
Why?
| | Apoptosis | 1 | 2013 | 52 | 0.030 |
Why?
| | Species Specificity | 1 | 2012 | 10 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2012 | 22 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 126 | 0.030 |
Why?
| | Survival Analysis | 1 | 2012 | 50 | 0.030 |
Why?
| | Body Weight | 1 | 2012 | 52 | 0.030 |
Why?
| | HapMap Project | 1 | 2012 | 3 | 0.030 |
Why?
| | Genes | 1 | 2012 | 10 | 0.030 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2012 | 1 | 0.030 |
Why?
| | Genes, RAG-1 | 1 | 2012 | 1 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2012 | 12 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2012 | 19 | 0.030 |
Why?
| | Gene Expression | 1 | 2012 | 67 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 71 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2015 | 816 | 0.030 |
Why?
| | Receptors, Interleukin-7 | 1 | 2011 | 2 | 0.020 |
Why?
| | Heterozygote | 1 | 2011 | 26 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 5 | 0.020 |
Why?
| | Biological Transport | 1 | 2011 | 19 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 26 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2011 | 58 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2011 | 115 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 101 | 0.020 |
Why?
| | Liver | 1 | 2011 | 126 | 0.020 |
Why?
| | DNA Breaks | 1 | 2009 | 2 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2009 | 3 | 0.020 |
Why?
| | Gene Rearrangement | 1 | 2009 | 7 | 0.020 |
Why?
| | Phorbol Esters | 1 | 2008 | 1 | 0.020 |
Why?
| | Receptors, Fc | 1 | 2008 | 1 | 0.020 |
Why?
| | src-Family Kinases | 1 | 2008 | 1 | 0.020 |
Why?
| | Ionophores | 1 | 2008 | 3 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2008 | 13 | 0.020 |
Why?
| | Down-Regulation | 1 | 2008 | 15 | 0.020 |
Why?
| | Kinetics | 1 | 2008 | 31 | 0.020 |
Why?
| | Electrocoagulation | 1 | 1999 | 1 | 0.010 |
Why?
| | Ornithine Decarboxylase | 1 | 1999 | 1 | 0.010 |
Why?
| | Ki-67 Antigen | 1 | 1999 | 7 | 0.010 |
Why?
| | Genes, p53 | 1 | 1999 | 5 | 0.010 |
Why?
| | Epithelium | 1 | 1999 | 8 | 0.010 |
Why?
| | Omeprazole | 1 | 1999 | 13 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1999 | 48 | 0.010 |
Why?
| | Biopsy | 1 | 1999 | 60 | 0.010 |
Why?
| | Proton Pump Inhibitors | 1 | 1999 | 18 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 1999 | 151 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|